Transactions on Materials, Biotechnology and Life Sciences
ISSN: 2960-1932, eISSN: 2960-2319 | Volume 7
MISBP 2024

Bioinformatic Approaches in Neurodegenerative Diseases

Zhuozhi Liu *

College of International Education, Beijing University of Chemical Technology, Beijing, China

* Corresponding Author Email: lzz20051213@gmail.com

Abstract. Neurodegenerative diseases (NDDs), including Alzheimer's and Parkinson's, affect the central nervous system, causing progressive loss of cognitive and motor functions. As the global population ages, the prevalence of NDDs rises, imposing significant burdens on patients, families, and society. Despite extensive research, the diagnosis and treatment of NDDs remain challenging due to the complexity of their pathological mechanisms. Traditional methods, such as experimental biology and clinical observation, offer insights but are limited in scope. Bioinformatics, an interdisciplinary field combining biology, computer science, and information technology, provides new opportunities for advancing NDD research. It facilitates the analysis of genomics and proteomics data, aids in drug discovery, and enhances the construction of disease models. This study explores the applications of bioinformatics in NDD research, highlighting its role in identifying disease-associated genes, understanding molecular mechanisms, and discovering potential therapies. Case studies demonstrate how bioinformatics tools can improve research outcomes. The study concludes with a discussion on future research directions and the potential of bioinformatics to develop novel diagnostic and therapeutic approaches for NDDs. Continued advancements in bioinformatics and interdisciplinary collaboration are expected to deepen our understanding of these diseases and lead to more effective treatments.

Keywords: Neurodegenerative Diseases; Bioinformatics; applications of bioinformatics.

1. Introduction

Neurodegenerative diseases (NDDs) constitute a category of conditions that impact either the central nervous system (CNS) or the peripheral nervous system (PNS). These disorders are predominantly defined by a gradual deterioration of neuronal cells and a subsequent collapse of the neural network's functionality. These diseases, which include Alzheimer's disease, Parkinson's disease, and Huntington's chorea, are characterized by progressive neuronal loss and dysfunction, leading to severe deterioration of cognitive and motor abilities. With the aging of the global population, the incidence of neurodegenerative diseases is increasing year by year, placing a heavy burden on patients, families, and society. Despite extensive research on these diseases by scientists in the past decades, the diagnosis and treatment of these diseases still face great challenges at present due to the complexity and heterogeneity of their pathomechanisms.

Traditional research methods, such as experimental biology and clinical observation, while providing valuable information for our understanding of neurodegenerative diseases, are often limited by the depth and breadth of research. Bioinformatics, as an interdisciplinary discipline, provides new perspectives and tools for the study of neurodegenerative diseases by integrating biology, computer science and information technology. The application of bioinformatics not only accelerates the analysis of genomic data such as genomics and proteomics, but also facilitates drug discovery and design, as well as the construction of disease models. The abnormal deposition of misfolded protein aggregates is a major feature of neurodegenerative diseases.This occurrence initiates a cascade of internal cellular disruptions that result in cellular malfunction and eventually cell demise, with a gradual decline in the functionality of nerve cells. Initially, these conditions are challenging to identify, as unique indicators and manifestations emerge slowly until the later phases. In clinical settings, they are often accompanied by symptoms such as motor dysfunction, Parkinson's disease, or cognitive decline.

The purpose of this research is to clarify the importance and potential future directions of bioinformatics in the field of neurodegenerative disease studies. The epidemiology and clinical features of neurodegenerative diseases are initially presented, succeeded by an examination of the challenges inherent in their study and the constraints of current methodologies. Subsequently, an overview is provided of the utilization of bioinformatics in genomics, proteomics, drug discovery and design, and the realms of data integration and systems biology. Case studies are employed to illustrate the capacity of bioinformatics tools and methodologies to aid scientists in the identification of genes associated with disease, the comprehension of molecular disease mechanisms, the discovery of potential therapeutic agents, and the construction of disease models. The study culminates in a discussion on the challenges and prospective research directions for bioinformatics in the study of neurodegenerative diseases, along with its potential to foster the development of innovative diagnostic tools and therapeutic strategies.

This study is designed to furnish researchers in the field of neurodegenerative diseases with a thorough compendium of bioinformatics tools and methodologies, coupled with innovative concepts and future research directions. It is posited that the ongoing evolution of bioinformatics technology, in conjunction with enhanced interdisciplinary cooperation, will deepen the comprehension of neurodegenerative diseases. Such advancements are anticipated to culminate in the development of more efficacious diagnostic and therapeutic instruments for patient care.

2. Genomics and genetic data analysis

2.1. The role of genomics in the study of neurodegenerative diseases

Genomics, the science of studying the structure, function, evolution, and interactions of genomes, has provided a new perspective on the study of neurodegenerative diseases. Through genome sequencing technology, scientists are able to identify genetic variants associated with diseases, including single nucleotide polymorphisms (SNPs), copy number variants (CNVs) and structural variants (SVs). The discovery of these genetic variants not only helps us understand the genetic basis of diseases, but also offers the possibility of early diagnosis, risk assessment and personalized treatment of diseases [1].

2.2. Bioinformatics tools and genetic data analysis

With the development of high-throughput sequencing technologies, large amounts of genetic data are being generated, which require powerful bioinformatics tools for analysis and interpretation [2]. Bioinformatics tools, such as genome browsers, sequence alignment tools, variant detection algorithms, and gene expression analysis software, have become indispensable tools for researchers. These tools can help researchers extract valuable information from massive amounts of data, identify disease-associated genes and variants, and analyze changes in gene expression patterns. Three commonly used analyzers and the bioinformatics tools are genome browser and data visualization, sequence comparison and mutation detection, gene expression analysis.

Genome browsers such as the UCSC Genome Browser and Ensembl provide researchers with an intuitive platform to view and analyze genomic data. These tools allow users to search and visualize genes, SNPs, CNVs, and other genetic variants in specific regions of the genome, as well as their distribution across populations and individuals [3]. Sequence comparison tools such as BLAST and Clustal Omega enable researchers to compare DNA sequences between different species or individuals to identify homology and differences. Variation detection algorithms, such as GATK and SAMtools, are widely used in the analysis of high-throughput sequencing data to identify new or known genetic variants [4, 5]. Gene expression analysis software, such as DESeq2 and edgeR, is specifically designed to analyze RNA sequencing data and identify genes with altered expression levels under specific conditions. These changes may be associated with the development of neurodegenerative diseases, providing clues to the molecular mechanisms of the disease [6].

As sequencing technology advances and data volumes increase, bioinformatics tools are evolving to accommodate more complex data analysis needs. For example, the application of machine learning and artificial intelligence technologies has enabled researchers to extract deeper biological meaning from large-scale genetic data and identify complex genetic patterns associated with diseases [7].

2.3. Case Studies

Through specific case studies, an intuitive understanding of the application of genomics and bioinformatics in neurodegenerative disease research can be achieved. For example, the ε4 variant of the APOE gene is recognized as a major genetic contributor to the risk of developing Alzheimer's disease (AD). Genomic association studies (GWAS) and bioinformatics analysis have revealed that the APOE ε4 allele is correlated with an increased risk of developing AD [8]. Furthermore, by comparing genomic data across various patient populations, researchers have been able to identify additional genetic variants that may impact disease progression. These findings not only deepen our comprehension of the genetic factors that underpin the condition but also provide valuable clues for devising innovative treatment approaches.

3. Proteomics and neurodegenerative diseases

3.1. Significance of proteomics research

Proteomics, as a key scientific field in the post-genomic era, focuses on analyzing the expression pattern, structure and function of all proteins in a cell or tissue. In the study of neurodegenerative diseases, proteomics provides a window into the molecular mechanisms of disease. Since proteins are the primary performers of cellular functions, their states and interactions are directly linked to disease onset and progression. For example, protein misfolding, aberrant aggregation, or loss of function is a central feature of many neurodegenerative diseases, such as β-amyloid plaques and tau protein tangles in Alzheimer's disease, and α-synuclein aggregation in Parkinson's disease [9].

3.2. Bioinformatics in proteomics data analysis

In the realm of proteomics data analysis, bioinformatics plays an indispensable role. The acquisition of proteomics data is typically achieved through high-throughput techniques such as mass spectrometry. These methods provide quantitative information on proteins and detailed data on post-translational modifications. The complexity and volume of these data necessitate the use of advanced bioinformatics tools for processing and analysis [10].

Bioinformatics applications in this process encompass several key areas. Firstly, protein identification is facilitated by search engines such as Mascot or MaxQuant. These tools compare mass spectrometry data with a protein database to identify proteins in a sample. Secondly, quantitative analysis is performed to compare changes in protein expression across different samples or conditions. This can be achieved through labeling methods, such as iTRAQ or TMT, or label-free methods like Label-free quantification.

Additionally, the analysis of protein-protein interaction (PPI) networks is an essential component of proteomics data analysis. This involves constructing PPI networks using resources like the STRING database or Cytoscape software. Such analysis helps to reveal the potential roles and interactions of proteins in disease pathways. Lastly, pathway analysis is conducted to map identified proteins to biological pathways through databases such as KEGG or Reactome. This mapping is essential for understanding the functional roles of proteins in disease mechanisms.

In summary, bioinformatics is integral to the analysis of proteomics data, enabling the identification of proteins, quantitative analysis of protein expression, construction of PPI networks, and mapping of proteins to biological pathways. These applications collectively contribute to a comprehensive understanding of protein functions and their implications in various biological processes and diseases.

3.3. Metabolic pathways and disease mechanisms

Proteomics studies have revealed significant changes in protein expression and function in neurodegenerative diseases, which are often associated with dysregulation of key metabolic pathways. For example, mitochondrial dysfunction is implicated in many neurodegenerative diseases, affecting energy metabolism and cellular stress responses [11]. By analyzing proteomic data, researchers can identify key proteins in specific pathways and understand how changes in their expression affect cell function and disease progression.

3.4. Case Studies

In Alzheimer's disease research, proteomics has revealed a wide range of protein changes associated with the disease, including proteins linked to inflammatory responses, cell death and synaptic dysfunction [12]. By examining the protein profiles of brain tissue from individuals with the disease and those without, scientists can pinpoint potential biomarkers and targets for treatment. For instance, alterations in the levels of certain heat shock proteins might be linked to stress reactions in neurons, which could justify the creation of treatments aimed at these proteins.

In summary, proteomics and bioinformatics play a crucial role in the study of neurodegenerative diseases. By revealing disease-related protein changes and metabolic pathways, these disciplines provide us with powerful tools to understand, diagnose, and treat these complex diseases. With advances in technology and innovations in data analysis methods, the application of proteomics in neurodegenerative disease research will be even more promising.

4. Drug discovery and design

4.1. Current status of drug development for neurodegenerative diseases

Drug development for neurodegenerative diseases is a challenging area. Currently, therapeutic options for these diseases are limited, and most treatments provide only symptomatic relief rather than disease-modifying therapies. For example, therapeutic agents for Alzheimer's disease focus on improving cognitive function and slowing disease progression, while treatments for Parkinson's disease focus on supplementing dopamine or inhibiting its degradation. These treatments do not prevent progressive disease deterioration, reflecting the limitations of current drug development [13].

4.2. Virtual screening and molecular docking techniques

One of the key applications of bioinformatics in drug discovery is virtual screening, a technique for rapidly identifying potential drug candidates from a large number of compounds by computational methods. Virtual screening can screen potential drugs based on structural, functional, or phenotypic information by predicting compound-drug target interactions. Molecular docking technology is an important component of virtual screening, which predicts the binding affinity and specificity of compounds by modeling their interactions with biological targets [14].

4.3. Case Studies

In drug discovery for Alzheimer's disease, bioinformatics tools have been used to identify and optimize inhibitors that target beta-amyloid. For example, through molecular docking techniques, researchers have been able to screen for small molecules that may interact with specific binding sites of β-amyloid that may help to inhibit its aggregation or facilitate its clearance. In Parkinson's disease research, bioinformatics has also been used to discover potential drugs against α-synuclein by analyzing its structural features and aggregation mechanisms and designing compounds that can prevent its abnormal aggregation [15].

4.4. Future directions in drug discovery

The future of drug discovery will rely more heavily on bioinformatics tools and methods to improve the efficiency and success of drug development. This includes the development of more accurate computational models to predict drug-target interactions, the use of machine learning algorithms to identify disease-related biomarkers, and the use of network pharmacology to discover multi-target drugs. In addition, with the rise of personalized medicine, bioinformatics will play a key role in designing customized treatments for specific patient groups.

Employing these sophisticated bioinformatics methodologies, researchers are enabled to more effectively identify and design potential therapeutic agents for neurodegenerative diseases, thereby offering renewed hope to patients. As technology continues to evolve, there is an expectation that more effective therapies will be developed in the future. These improvements aim to improve the well-being of patients and slow down the progression of these diseases.

5. Data integration and systems biology

5.1. Multi-omics data integration

In the field of neurodegenerative disease research, the integration of multi-omics data has become a potent approach that offers a holistic view of the disease's intricacies by amalgamating information from various genomic, transcriptomic, proteomic, and metabolomic levels. This integrative approach can reveal interactions and networks between biomolecules, thus helping researchers to identify key biomarkers and therapeutic targets for diseases. For instance, by examining gene expression data in conjunction with protein abundance data, scientists can pinpoint critical genes and proteins that govern particular biological processes. In addition, the integration of multi-omics data can reveal how genetic variation affects protein function and metabolic pathways, providing new insights into the molecular mechanisms of disease [16].

5.2. Systems Biology in Neurodegenerative Diseases

Systems biology offers a comprehensive framework for understanding the complexity of neurodegenerative diseases by constructing and analyzing intricate biological network models. This holistic approach enables researchers to model and decipher the multifaceted interactions that contribute to the disease process. Several applications of systems biology in neurodegenerative disease research are particularly noteworthy [17].

In Alzheimer's disease research, systems biology models have been instrumental in simulating the intricate processes of β-amyloid (Aβ) production, aggregation, and clearance. These models incorporate the processing of the Aβ precursor protein (APP), genetic variations in Aβ, and a spectrum of molecular and cellular mechanisms associated with Aβ clearance. By employing these models, researchers can pinpoint key factors that regulate the dynamic equilibrium of Aβ levels and explore potential therapeutic interventions to modulate these factors.

Parkinson's disease studies have also benefited from systems biology through the construction of protein-protein interaction (PPI) networks. These networks investigate the impact of α-synuclein aggregation on cellular function, revealing the multitude of proteins that interact with α-synuclein and their contributions to disease progression. Analysis of these networks aids in identifying potential targets for disease modification and in discovering drugs that may mitigate the progression of the disease.

Amyotrophic lateral sclerosis (ALS) research has been advanced by systems biology approaches that analyze disease-related metabolic pathways, including glutamate metabolism, mitochondrial function, and protein homeostasis. By integrating gene expression, proteomic, and metabolomic data, researchers have developed metabolic network models of ALS. These models elucidate the connection between metabolic pathway abnormalities and neuronal damage, offering a theoretical foundation for the development of therapeutic strategies that target these pathways.

Lastly, Huntington's chorea, a genetic disorder stemming from mutations in the Huntington protein (HTT), has been studied using systems biology to construct models of signaling pathways. These models examine the effects of mutant HTT on cell signaling and gene expression, providing insights into the molecular pathways implicated in the disease. Such models have been invaluable in guiding the development of therapeutic strategies that target specific signaling pathways.

In summary, systems biology has been pivotal in advancing researchers' understanding of neurodegenerative diseases by modeling complex interactions and providing a platform for the identification of therapeutic targets. Through the analysis of biological networks, researchers are better equipped to uncover the underlying mechanisms of these diseases and to develop novel treatments.

5.3. Cyberpharmacology and Personalized Therapy

Network pharmacology is an emerging discipline that provides new ideas for drug discovery and personalized therapy by analyzing the network of interactions between drugs and biological targets. In the treatment of neurodegenerative diseases, network pharmacology can help researchers identify multi-target drugs that can act simultaneously on multiple pathological pathways of the disease. For example, by analyzing the network of drug interactions with neurodegenerative disease-related proteins, researchers can identify drugs with multi-target effects that may have a broader therapeutic effect on the disease. Furthermore, network pharmacology can facilitate personalized treatment by considering an individual's genetic makeup and biomarkers, allowing for the creation of a customized treatment regimen for each patient [18].

By employing these methodologies, data integration and systems biology not only enhance our comprehension of neurodegenerative diseases, but also open up new avenues for diagnosing, treating, and preventing these conditions. With technological advances and innovations in data analysis methods, the application of these methods in neurodegenerative disease research will be even more promising.

6. Challenges and future directions

6.1. Limitations of the current study

Despite the remarkable progress of bioinformatics in the study of neurodegenerative diseases, several challenges and limitations remain. First, the complexity and heterogeneity of neurodegenerative diseases lead to difficulties in understanding disease mechanisms. In addition, data heterogeneity is a major issue, as the techniques and methods used in different studies can make it difficult to compare and integrate results. Algorithmic complexity is also a challenge, as existing bioinformatics tools may have difficulty processing and interpreting large and complex datasets. Finally, big data processing issues, including data storage, transmission and analysis, require more efficient computational resources and methods.

6.2. Directions for future research

Future research needs to address current limitations and explore new research directions. More precise integration of multi-omics data is necessary because it can provide a more comprehensive understanding of disease. For example, by integrating genomic, transcriptomic, proteomic, and metabolomic data, researchers can reveal interactions and effects at different biomolecular levels. In addition, the development of more efficient computational methods and algorithms is essential to process and analyze the growing volume of data. These methods should be able to handle large-scale datasets while maintaining the accuracy and interpretability of the analysis. In addition, closer integration of bioinformatics with clinical research will help to translate basic science research into clinical applications, for example by identifying biomarkers and developing personalized treatments.

6.3. Potential of Bioinformatics Technology

The impact of bioinformatics technologies on the advancement of neurodegenerative disease research is profound and holds immense potential for future breakthroughs. As these technologies continue to evolve, their utility in various aspects of research is expected to expand significantly [19].

One of the most promising applications of bioinformatics is in the realm of early diagnosis. By meticulously analyzing genetic and proteomic data, bioinformatics tools can aid in the identification of biomarkers that are indicative of the early stages of neurodegenerative diseases. This capability is crucial, as it enables healthcare providers to make early diagnoses and intervene promptly, potentially altering the course of the disease.

Additionally, bioinformatics is instrumental in creating disease models. By building these models with bioinformatics tools, scientists can simulate the course of the disease and how it responds to drugs. This offers valuable predictive insights that can inform drug development and the planning of clinical trials, potentially speeding up the process of bringing effective therapies to market.

The realm of precision medicine is poised to gain immensely from bioinformatics. By examining a person's genetic and proteomic data, bioinformatics can aid in crafting personalized treatment strategies that are customized to each patient's distinct genetic profile. This method has the capacity to markedly enhance therapeutic outcomes by ensuring that treatments are specifically directed and fine-tuned for individual patients.

In addition to these applications, bioinformatics technologies are instrumental in drug discovery and repositioning. They can expedite the identification of new drugs and the repurposing of existing ones, particularly for complex targets associated with neurodegenerative diseases. This can lead to the development of novel therapeutic strategies and the enhancement of existing treatments.

In conclusion, bioinformatics is already playing a vital role in the study of neurodegenerative diseases, and its importance is set to grow as technology and methodologies advance. The integration of bioinformatics into research provides new strategies and offers hope for improved diagnosis, treatment, and prevention of these debilitating conditions. As the ability to analyze and interpret complex biological data continues to improve, so too will the capacity to combat neurodegenerative diseases and enhance the quality of life for those affected.

7. Conclusion

Considerable advancements have been achieved in utilizing bioinformatics for neurodegenerative disease studies, offering a robust instrument for deciphering the molecular underpinnings of these intricate illnesses. By synthesizing and scrutinizing vast datasets encompassing genetics, proteomics, and clinical information, bioinformatics has uncovered potential biomarkers and targets for treatment, thus bridging the gap between foundational research and practical clinical use.

Interdisciplinary collaboration is particularly important in the study of neurodegenerative diseases. Close collaboration among bioinformaticians, geneticists, molecular biologists, clinicians and computer scientists can facilitate the sharing and analysis of data and accelerate the generation of new discoveries. Such collaboration not only helps to solve technical difficulties encountered in research, but also facilitates the clinical application of research results.

Technological advances, especially the development of high-throughput sequencing and mass spectrometry technologies, have provided abundant data resources for the study of neurodegenerative diseases. At the same time, improvements in computing power and innovations in algorithms have made it possible to process and analyze these data. Future technological developments, such as the application of artificial intelligence and machine learning, will further promote the application of bioinformatics in neurodegenerative disease research.

Bioinformatics offers the possibility of personalized medicine, whereby customized treatment plans can be provided to patients by analyzing an individual's genetic background and proteomic information. This personalized approach to treatment is expected to improve outcomes, reduce side effects, and provide patients with a better quality of life.

Despite the remarkable progress of bioinformatics in neurodegenerative disease research, there are still some challenges, such as data heterogeneity, algorithmic complexity, and big data processing issues. Future research requires the development of more efficient data analysis tools and algorithms to handle the increasing amount of data and to improve the accuracy and interpretability of the analysis. Moreover, a tighter alliance between bioinformatics and clinical studies will aid in transforming fundamental scientific findings into practical medical uses and offer innovative approaches and techniques for diagnosing and treating neurodegenerative disorders.

In summary, bioinformatics has become an essential component of neurodegenerative disease research. It has significantly expedited the comprehension of disease mechanisms and has been instrumental in facilitating the discovery of novel therapeutics and the development of disease models. As technology continues to progress and interdisciplinary collaboration is further strengthened, it is anticipated that bioinformatics will assume an even more pivotal role in future research and therapeutic approaches for neurodegenerative diseases. This advancement is expected to translate into the provision of more effective diagnostic and therapeutic tools for patients, thereby enhancing their quality of life and potentially slowing the progression of these debilitating conditions.

References

[1] Du, R.-Q., Jin, L., & Zhang, F. (2011). Copy number variations in the human genome: Their mutational mechanisms and roles in diseases. HEREDITAS, 33(8), 857-869.

[2] Wang, X.-C., Yang, Z.-R., Wang, M., Li, W., & Li, S.-C. (2012). High-throughput sequencing technology and its application. China Biotechnology, 32(1), 109-114.

[3] Wang, J., Kong, L., Gao, G., & Luo, J. (2013). A brief introduction to web-based genome browsers. Briefings in Bioinformatics, 14(2), 131-143. https://doi.org/10.1093/bib/bbs029

[4] Crowe, M. L. (2005). SeqDoC: Rapid SNP and mutation detection by direct comparison of DNA sequence chromatograms. BMC Bioinformatics, 6, 133. https://doi.org/10.1186/1471-2105-6-133

[5] Wang, Q., Jia, P., & Li, F., et al. (2013). Detecting somatic point mutations in cancer genome sequencing data: A comparison of mutation callers. Genome Medicine, 5, 91. https://doi.org/10.1186/gm495

[6] Crowe, M. L. (2005). SeqDoC: Rapid SNP and mutation detection by direct comparison of DNA sequence chromatograms. BMC Bioinformatics, 6(1), 1-12.

[7] Xu, J., Yang, P., Xue, S., Sharma, B., Sanchez-Martin, M., Wang, F., ... & Parikh, B. (2019). Translating cancer genomics into precision medicine with artificial intelligence: Applications, challenges and future perspectives. Human Genetics, 138(2), 109-124.

[8] Ma, S., Wei, M., Ni, J., Li, T., Wang, X., Xu, S., & Li, X. (2019). Meta-analysis of the association between APOE e4 allele and psychobehavioral symptoms in Alzheimer's disease. China Medical Journal, 19(23), 79-84.

[9] Yuan, X., Yao, C., Chen, W., Wang, J., Huang, Y., Qu, Y., Zeng, H., Cui, E., & Liao, Y. (2024). Recent advance in different therapies for Alzheimer's disease. Guangzhou Medical Journal, 55(3), 236-244.

[10] Chen, C., Hou, J., Tanner, J. J., & Cheng, J. (2020). Bioinformatics methods for mass spectrometry-based proteomics data analysis. International Journal of Molecular Sciences, 21(8), 2873.

[11] Johri, A., & Beal, M. F. (2012). Mitochondrial dysfunction in neurodegenerative diseases. Journal of Pharmacology and Experimental Therapeutics, 342(3), 619-630.

[12] Butterfield, D. A. (2004). Proteomics: A new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Research, 1000(1-2), 1-7.

[13] Durães, F., Pinto, M., & Sousa, E. (2018). Old drugs as new treatments for neurodegenerative diseases. Pharmaceuticals, 11(2), 44.

[14] Surana, K. R., Ahire, E. D., Sonawane, V. N., & Talele, S. G. (2021). Biomolecular and molecular docking: A modern tool in drug discovery and virtual screening of natural products. In Applied Pharmaceutical Practice and Nutraceuticals (pp. 209-223). Apple Academic Press.

[15] Surana, K. R., Ahire, E. D., Sonawane, V. N., & Talele, S. G. (2021). Biomolecular and molecular docking: A modern tool in drug discovery and virtual screening of natural products. In Applied Pharmaceutical Practice and Nutraceuticals (pp. 209-223). Apple Academic Press.

[16] Abbas, Z., Tayara, H., & Chong, K. T. (2022). Alzheimer's disease prediction based on continuous feature representation using multi-omics data integration. Chemometrics and Intelligent Laboratory Systems, 223, 104536.

[17] Wood, L. B., Winslow, A. R., & Strasser, S. D. (2015). Systems biology of neurodegenerative diseases. Integrative Biology, 7(7), 758-775.

[18] Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682-690.

[19] Benton, D. (1996). Bioinformatics: Principles and potential of a new multidisciplinary tool. Trends in Biotechnology, 14(8), 261-272.